Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.56 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13309358 | 1.00 | ADORA2A (0.56) | ADORA2AADORA2BP2RY12ADORA3ADORA1 | |
| SCHEMBL13309393 | 1.00 | ADORA2A (0.56) | ADORA2AADORA2BP2RY12ADORA3ADORA1 | |
| SCHEMBL13309392 | 0.93 | P2RY12 (0.49) | ADORA2AADORA2BP2RY12ADORA3ADORA1 | |
| SCHEMBL13337667 | 0.90 | ADORA2A (0.69) | ADORA2AADORA2BADORA3ADORA1PMP22 | |
| SCHEMBL13309292 | 0.90 | ADORA2A (0.69) | ADORA2AADORA2BADORA3ADORA1PMP22 | |
| SCHEMBL13309374 | 0.90 | P2RY12 (0.53) | ADORA2AADORA2BP2RY12ADORA3ADORA1 | |
| SCHEMBL13337718 | 0.90 | P2RY12 (0.53) | ADORA2AADORA2BP2RY12ADORA3ADORA1 | |
| SCHEMBL13309362 | 0.89 | ADORA2B (0.49) | ADORA2AADORA2BP2RY12ADORA3ADORA1 | |
| SCHEMBL13337751 | 0.89 | ADORA2B (0.59) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL13337752 | 0.89 | ADORA2B (0.49) | ADORA2AADORA2BP2RY12ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160250-A1 | METHOD FOR TREATING INFLAMMATORY CONDITIONS | INSPIRE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160250-A1 | METHOD FOR TREATING INFLAMMATORY CONDITIONS | P2RX1, P2RX7, P2RX2 | ADORA2A 28/4885ADORA2B 42/4885P2RY12 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.